Biologics and Sublingual Immunotherapy (NCT06027073) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Biologics and Sublingual Immunotherapy
150 participantsStarted 2024-05-01
Plain-language summary
Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:• \>18 years old
* A total IgE between 30-700 IU/mL
* Moderate asthma with perennial symptoms confirmed as HDM-driven asthma based on medical history and positive nasal provocation tests, partially controlled asthma;
* FEV1 \>70% at baseline;
* Positive skin prick test results for D. pteronyssinus, D. farinae
Exclusion Criteria:
* Sensitisation to other allergens with clinical signs not related to HDM
* Uncontrolled asthma,
* Other serious diseases or chronic unstable diseases
* Allergen immunotherapy during the past 5 years
* Contraindicating allergen immunotherapy and omalizumab treatment.
What they're measuring
1
Assess the effectiveness of combined therapy : omalizumab+ immunotherapy